Press Releases

Dec 13, 2021 11:00 am EST KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

Dec 4, 2021 8:00 am EST Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

Nov 29, 2021 8:00 am EST GBM AGILE Opens to Paxalisib in Canada

Nov 15, 2021 11:00 am EST Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

Nov 11, 2021 8:00 am EST PNOC Study in Childhood Brain Cancer Enrols First Patient

Nov 4, 2021 8:00 am EDT Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

Oct 6, 2021 10:00 am EDT Kazia Therapeutics to Present at LD Micro Main Event

Sep 10, 2021 12:30 pm EDT Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

Jul 21, 2021 10:00 am EDT Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

Jun 30, 2021 10:00 am EDT Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs